With effect from March 11, 2024, Telix Pharmaceuticals Limited is happy to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO).
In order to oversee Telix’s operations in the United States (U.S.), Dr. Patti joined the company in March 2021. In his capacity as the Americas region’s general manager and chief operating officer for the past three years, he has led ongoing market development for Telix in Brazil and Latin America (LATAM), oversaw the successful launches of Illuccix® in the United States and Canada, and played a significant role in the launch preparations for Telix’s follow-on imaging products, Zircaix®[1] and PixclaraTM[1] (pending regulatory approval). Before coming to work for Telix, Darren spent fifteen years in a number of capacities at Sofie Biosciences. Most recently, he served as Vice President of Operations, overseeing the Sofie-Lantheus PSMA-PET imaging program’s operationalization.
Darren is an Authorized Nuclear Pharmacist and has a Doctor of Pharmacy (Pharm.D.) from the University of Illinois at Chicago.
Darren has been an exemplary leader in our Americas region and fundamental to the success of our commercial operations and vertical integration strategy, said Dr. Christian Behrenbruch, Managing Director and Group CEO. As we grow into new commercial markets and strengthen our manufacturing capabilities to support our therapeutic and imaging programs, Darren is the perfect leader for our global operations function because of his extensive experience in radiopharmacy network management and operations and his intricate knowledge of the Telix business. As we get ready to launch more diagnostics and move into our next phase as a pioneer in therapeutic radiopharmaceuticals and precision medicine, I am excited to keep working closely with Darren in this new capacity.
Telix is a biopharmaceutical firm that specializes in the creation and marketing of medical devices that are related to diagnostic and therapeutic radiopharmaceuticals. Telix has overseas operations in the US, Europe (Belgium and Switzerland), and Japan. The company’s headquarters are located in Melbourne, Australia. With a focus on rare diseases and oncology, Telix is building a portfolio of clinical and commercial stage solutions to address important unmet medical needs.
Gallium-68 (68Ga) gozetotide injection, also referred to as 68Ga PSMA-11 and sold under the brand name Illuccix®, is Telix’s primary imaging product. It has received approval from Health Canada, the Australian Therapeutic Goods Administration (TGA), and the U.S. Food and Drug Administration (FDA). With FDA registration, Telix’s surgical gamma probe, SENSEI®, has been approved for use in the United States for minimally invasive and robotic-assisted procedures. It also bears the Conformité Européenne (CE) Mark, indicating that it is approved for use in the European Economic Area for the intraoperative detection of sentinel lymph nodes (SLNs). Except for the two products mentioned above, Illuccix® and SENSEI®, no Telix product has been granted a marketing authorization in any jurisdiction.
